Glomerular Microangiopathy-like Nephropathy Caused by Hyperthyroidism

Intern Med. 2024 Jun 15;63(12):1765-1770. doi: 10.2169/internalmedicine.2436-23. Epub 2023 Nov 6.

Abstract

A 49-year-old Japanese woman was admitted to our hospital with weight loss of 15 kg, nephrotic-range proteinuria (4.5 g/g.Cre), and hematuria over a 6-month period. She had received two doses of the coronavirus disease 2019 (COVID-19) vaccine one year before the onset of the disease, after which the estimated glomerular filtration rate increased. Laboratory tests and other tests led to a diagnosis of hyperthyroidism, and a kidney biopsy showed thrombotic microangiopathy-like glomerular microangiopathy comprising mainly glomerular endothelial cell damage. Thiamazole (30 mg) was started for the hyperthyroidism. Three months later, the thyroid function normalized, and two months later, the proteinuria and hematuria disappeared, suggesting that COVID-19 vaccination and these events were related.

Keywords: COVID-19 vaccination; TMA-like renal disease; glomerular microangiopathy; hyperthyroidism; tamoxifen.

Publication types

  • Case Reports

MeSH terms

  • Antithyroid Agents / therapeutic use
  • COVID-19 / complications
  • COVID-19 Vaccines / adverse effects
  • Female
  • Hematuria / etiology
  • Humans
  • Hyperthyroidism* / complications
  • Hyperthyroidism* / diagnosis
  • Kidney Diseases / diagnosis
  • Kidney Diseases / etiology
  • Kidney Glomerulus / pathology
  • Methimazole / therapeutic use
  • Middle Aged
  • Thrombotic Microangiopathies* / diagnosis
  • Thrombotic Microangiopathies* / etiology

Substances

  • Methimazole
  • Antithyroid Agents
  • COVID-19 Vaccines